MX2018011306A - Vector multimodal para infeccion de celulas dentriticas. - Google Patents

Vector multimodal para infeccion de celulas dentriticas.

Info

Publication number
MX2018011306A
MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A
Authority
MX
Mexico
Prior art keywords
cell
dendritic cell
cancer
cell infection
viral nucleic
Prior art date
Application number
MX2018011306A
Other languages
English (en)
Inventor
Soon-Shiong Patrick
Niazi Kayvan
Rabizadeh Shahrooz
Original Assignee
Nantcell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantcell Inc filed Critical Nantcell Inc
Publication of MX2018011306A publication Critical patent/MX2018011306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Los virus recombinantes y acidos nucleicos virales se contemplan que proporcionan a la celula infectada varias moleculas reguladoras que estimulan la actividad de la celula T y celula NK y que suprime la inhibicion de la actividad de la celula T y celula NK. Mas preferiblemente, el virus y acido nucleico viral incluira ademas una secuencia asociada al cancer humano, y especialmente una secuencia que codifica una pluralidad de antigenos asociados al cancer, antigenos especificos al cancer, y/o neoantigenos especificos al tumor o al paciente. Especialmente las moléculas reguladoras especificas incluyen CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), CD11 (LFA-1), y un inhibidor de CTLA-4.
MX2018011306A 2016-03-18 2017-03-20 Vector multimodal para infeccion de celulas dentriticas. MX2018011306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310551P 2016-03-18 2016-03-18
US201662313596P 2016-03-25 2016-03-25
PCT/US2017/023117 WO2017161360A2 (en) 2016-03-18 2017-03-20 Multimodal vector for dendritic cell infection

Publications (1)

Publication Number Publication Date
MX2018011306A true MX2018011306A (es) 2019-08-16

Family

ID=59850551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011306A MX2018011306A (es) 2016-03-18 2017-03-20 Vector multimodal para infeccion de celulas dentriticas.

Country Status (11)

Country Link
US (1) US20210198689A1 (es)
EP (1) EP3430148A4 (es)
JP (1) JP2019508044A (es)
KR (1) KR20180118198A (es)
CN (1) CN109312364A (es)
AU (1) AU2017233072B2 (es)
CA (1) CA3016389A1 (es)
IL (1) IL261812A (es)
MX (1) MX2018011306A (es)
SG (1) SG11201808058PA (es)
WO (1) WO2017161360A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201414021D0 (en) 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
JP6533011B2 (ja) 2015-08-25 2019-06-19 ナントミクス，エルエルシー 高正確度変異体コールのためのシステムおよび方法
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
AU2017290803A1 (en) 2016-06-30 2019-01-24 Nant Holdings Ip, Llc Nant cancer vaccine
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018041838A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
EP3630143B1 (en) 2017-06-01 2023-06-07 Akamis Bio Limited Oncolytic virus and method
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361988T1 (de) * 1998-12-09 2007-06-15 Us Gov Health & Human Serv Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
AU2002307145B2 (en) * 2001-04-05 2007-11-29 The John Hopkins University Chimeric vaccines
WO2003039592A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
US20040156828A1 (en) * 2003-01-07 2004-08-12 Ruian Xu Adeno-associated virus mediated B7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers
WO2006108241A1 (en) * 2005-04-14 2006-10-19 The University Of Queensland Immunomodulating compositions and uses therefor
EP2619312A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
PT2751279T (pt) * 2011-08-31 2017-12-29 St Jude Children`S Res Hospital Métodos e composições para detetar o nível de atividade de exocitose lisossomal e métodos de utilização
CN102533859A (zh) * 2012-01-12 2012-07-04 中国人民解放军第二军医大学 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用
WO2014066443A1 (en) * 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
KR102006527B1 (ko) * 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
JP6535337B2 (ja) * 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
AU2014368898B2 (en) * 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
US11028143B2 (en) * 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
IL248507B (en) * 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule

Also Published As

Publication number Publication date
SG11201808058PA (en) 2018-10-30
EP3430148A2 (en) 2019-01-23
WO2017161360A4 (en) 2017-11-16
IL261812A (en) 2018-10-31
WO2017161360A2 (en) 2017-09-21
WO2017161360A3 (en) 2017-10-26
CN109312364A (zh) 2019-02-05
AU2017233072B2 (en) 2020-12-24
US20210198689A1 (en) 2021-07-01
CA3016389A1 (en) 2017-09-21
EP3430148A4 (en) 2020-01-01
KR20180118198A (ko) 2018-10-30
JP2019508044A (ja) 2019-03-28
AU2017233072A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2018011306A (es) Vector multimodal para infeccion de celulas dentriticas.
GB2573664A (en) Viral methods of T cell therapy
PH12019501130A1 (en) Viral delivery of neoantigens
CY1122571T1 (el) Μακροκυκλικοι αναστολεις των αλληλεπιδρασεων πρωτεϊνων/πρωτεϊνων ρd-1/ρd-l1 και cd80(β7-1)/ρd-l1
EP4219696A3 (en) Oncolytic virus strain
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
EP4197551A3 (en) Adoptive cell transfer and oncolytic virus combination therapy
WO2017069958A3 (en) Modulation of novel immune checkpoint targets
PH12017500441A1 (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
PH12018500855A1 (en) Herpes simplex virus vaccine
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
MX2017011960A (es) Inmunomoduladores.
MX2017010129A (es) Inmunomoduladores.
MX2019004215A (es) Insercion de genes dirigida para terapia de celulas inmunes mejorada.
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
MX2017004542A (es) Inmunomoduladores.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
JP2019520061A5 (es)
EA201790167A1 (ru) Цитомегаловирус человека, содержащий экзогенные антигены
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
MX2018006373A (es) Produccion de virus en cultivos celulares.